At a glance
ClinicalIndex Comparison Record- ✓Age 18–55 years
- ✓BMI >18.5 kg/m²
- ✓At least 8 years formal education with appropriate reading and comprehension skills
- ✓Able and willing to provide written informed consent
- ✕Known infection with Mycobacterium tuberculosis (MTB)
- ✕HIV positive status
- ✕Hepatitis B or C infection
- ✕History of allergy or hypersensitivity to imatinib, isoniazid, or rifabutin
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
IMPACT-TB (Imatinib Mesylate Per Oral as a Clinical Therapeutic for TB): A Phase II Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin
In Brief
A Phase 2 clinical trial evaluating Imatinib, Isoniazid, and 1 other intervention for Tuberculosis. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, and effects of imatinib on myelopoiesis in adults when given with and without isoniazid and rifabutin. The results of this trial will determine the imatinib dose to be studied in a subsequent Phase IIB treatment trial of imatinib as an adjunctive therapy with an antimicrobial regimen (rifabutin, pyrazinamide (PZA), isoniazid (INH) and ethambutol) for drug-sensitive TB.
Study Details
Timeline
Interventions
Tablets, administered orally
300 mg tablets, administered orally
300 mg capsules, administered orally